Eukaryotic translation initiation complex (eIF complex) (eIF complex)

The general protein translation machinery, primarily the eukaryotic translation initiation complex (eIF4F), is the multi-protein system responsible for the synthesis of proteins from mRNA templates. In tumor cells, this machinery is often hyperactivated to support the increased demand for proteins that drive cell cycle progression, angiogenesis, and survival, such as c-Myc and VEGF (Bhat et al., 2015, Nature Reviews Drug Discovery). The eIF4F complex—comprising the cap-binding protein eIF4E, the RNA helicase eIF4A, and the scaffold protein eIF4G—serves as a central node where major oncogenic signaling pathways like PI3K/AKT/mTOR and MAPK/ERK converge (Pelletier et al., 2015, Nature Reviews Drug Discovery). Therapeutic targeting of this machinery involves various strategies, including mTOR inhibitors that prevent eIF4F assembly, direct eIF4A inhibitors like zotatifin, and elongation inhibitors such as omacetaxine mepesuccinate (Gandhi et al., 2014, Clinical Cancer Research). While these drugs can effectively suppress the production of multiple oncogenic drivers simultaneously, they also pose significant safety challenges. The most notable concerns include systemic toxicities like myelosuppression and gastrointestinal distress, as protein synthesis is a fundamental process required by all healthy, dividing cells.

Other names

General protein translation machineryTranslational apparatuseIF4F complexRibosomeProtein synthesis machinery

Inhibition of the eIF4F complex assembly, inhibition of eIF4A helicase activity, or interference with the ribosomal A-site to prevent elongation.